Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | TACR1 | P25103 | 8/20 | 0.55 |
| ▸ | NMBR | P28336 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.49 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19068574 | 1.00 | MAPT (0.60) | MAPTLMNAGAAHTTTACR1 | |
| SCHEMBL17938396 | 0.94 | MAPT (0.60) | MAPTLMNAGAAHTTTACR1 | |
| SCHEMBL17938398 | 0.93 | MAPT (0.62) | MAPTLMNAGAAHTTTACR1 | |
| SCHEMBL16645287 | 0.93 | MAPT (0.62) | MAPTLMNAGAAHTTTACR1 | |
| SCHEMBL16634516 | 0.87 | MAPT (0.62) | MAPTLMNAGAAHTTTACR1 | |
| SCHEMBL16645245 | 0.85 | MAPT (0.61) | MAPTLMNAGAAHTTTACR1 | |
| SCHEMBL17938406 | 0.85 | MAPT (0.61) | MAPTLMNAGAAHTTTACR1 | |
| SCHEMBL1318661 | 0.85 | NMBR (0.73) | MAPTLMNAGAAHTTTACR1 | |
| SCHEMBL29401413 | 0.85 | NMBR (0.73) | MAPTLMNAGAAHTTTACR1 | |
| SCHEMBL17319524 | 0.85 | NMBR (0.73) | MAPTLMNAGAAHTTTACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9695174-B2 | Inhibitor of breast cancer resistance protein (BCRP) | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2017-07-04 | — | — | US | disclosed |
| US-9695174-B2 | Inhibitor of breast cancer resistance protein (BCRP) | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2017-07-04 | — | — | US | disclosed |
| US-20160214984-A1 | INHIBITOR OF BREAST CANCER RESISTANCE PROTEIN (BCRP) | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-07-28 | — | — | US | disclosed |
| US-20160214984-A1 | INHIBITOR OF BREAST CANCER RESISTANCE PROTEIN (BCRP) | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-07-28 | — | — | US | disclosed |
| WO-2015054132-A1 | INHIBITOR OF BREAST CANCER RESISTANCE PROTEIN (BCRP) | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2015-04-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160214984-A1 | INHIBITOR OF BREAST CANCER RESISTANCE PROTEIN (BCRP) | BRCA1, ABCC1, IMPA1 | MAPT 3799/4885LMNA 4679/4885GAA 4816/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.